Indication · Cardiometabolic disease

Cardiovascular risk reduction

Also known as: MACE reduction · major adverse cardiovascular events

Cardiovascular risk reduction has 2 mapped peptide assets across 1 target.

Targets

GLP-1R

Activates incretin signaling to potentiate glucose-dependent insulin secretion, delay gastric emptying, and reduce appetite.

Asset	Stage	Sponsors
Semaglutide	Approved	Novo Nordisk
Retatrutide	Phase 3	Eli Lilly

Registry ID	Phase	Title	Status
NCT04184622	Phase 3	A Research Study to Look at How Semaglutide Works Compared to Placebo in People With Overweight or Obesity	Completed
NCT05567796	Phase 3	A Study of Retatrutide in Participants With Obesity or Overweight	Recruiting

Clinical trial registry and NEJM publication

Clinical trial registry and conference presentation